Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company CBT Pharmaceuticals Inc.
DescriptionIgG4 humanized mAb against programmed cell death 1 (PD-1; PDCD1; CD279)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentIND
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerWalvax Biotechnology Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today